Phase I study of 12-O-tetradecanoylphorbol-13-acetate in patients with relapsed or refractory hematologic malignancies/bone marrow disorders

Trial Profile

Phase I study of 12-O-tetradecanoylphorbol-13-acetate in patients with relapsed or refractory hematologic malignancies/bone marrow disorders

Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2015

At a glance

  • Drugs Tetradecanoylphorbol acetate (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Adenocarcinoma; Aplastic anaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Hodgkin's disease; Leukaemia; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Ovarian disorders; Prostate cancer; Renal cell carcinoma; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Feb 2015 According to a Rich Pharmaceuticals media release, the results of this trial were published in Cancer Chemotherapy and Pharmacology.
    • 02 Feb 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 21 Dec 2005 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top